?The adjuvant use of IRE1 inhibitors has been reported in multiple cancers, including ?triple-negative breast cancer, ?glioblastoma multiforme, acute myeloid leukemia, and ?multiple myeloma [179]. Here, ERN1 is linked to plasma cell myeloma.